首页> Expert review of clinical immunology> Usability, efficacy, and safety of candidate tocilizumab biosimilar CT-P47 self-administration via auto-injector and pre-filled syringe in patients with rheumatoid arthritis: a single-arm, open-label, phase 3 study.

Usability, efficacy, and safety of candidate tocilizumab biosimilar CT-P47 self-administration via auto-injector and pre-filled syringe in patients with rheumatoid arthritis: a single-arm, open-label, phase 3 study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Gerd,Burmester

第一单位： Charité University Medicine, Berlin, Germany.

作者： Gerd,Burmester ^[1] ; Piotr Adrian,Klimiuk ^[2] ; Jakub,Trefler ^[3] ; Janusz,Jaworski ^[4] ; SungHyun,Kim ^[5] ; YunJu,Bae ^[5] ; DaBee,Jeon ^[5] ; HyunSeung,Lee ^[5] ; JiYoung,Jang ^[5] ; ChanKyoung,Hwang ^[5] ; HoJae,Lee ^[5] ; Josef S,Smolen ^[6]

作者单位： Charité University Medicine, Berlin, Germany. ^[1] Inter Clinic Piotr Adrian Klimiuk, Białystok, Poland.;Department of Rheumatology and Internal Diseases, Medical University of Bialystok, Bialystok, Poland. ^[2] REUMA RESEARCH, Warsaw, Poland. ^[3] Klinika Reuma Park sp. z o.o. sk, Warsaw, Poland. ^[4] Celltrion, Inc., Incheon, Republic of Korea. ^[5] Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. ^[6]

关键词 Auto-injector biosimilar interleukin-6 pre-filled syringe rheumatoid arthritis usability